ClinicalTrials.gg
AvailableNCT07218224Updated Oct 20, 2025

Expanded Access:18F-Fluorocholine for the Detection of Parathyroid Adenomas

An expanded access record providing 18F-Fluorocholine (FCH) and Positron emission tomography (PET) in Parathyroid Adenomas, sponsored by Thomas Hope. Available. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2025-10-20.

Sponsored by Thomas Hope · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Individual patients · Treatment IND/protocol
Ages
13 Years and older
Sex
All
01

Study summary

This expanded access protocol is proposed to allow University of California San Francisco (UCSF) patients additional access to 18F-fluorocholine (FCH) Positron Emission Tomography (PET) imaging for localization of parathyroid adenomas.

Read the detailed description

No health outcome measures will be obtained under this protocol.

02

Conditions studied

  • Parathyroid Adenomas

Browse trials for

03

In context

Parathyroid Neoplasms

63 studies on the registry are indexed under Parathyroid Neoplasms; 19 are open to participants now.

Browse Parathyroid Neoplasms studies →

Lead sponsor

Thomas Hope is the lead sponsor of 15 studies on the registry; 5 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 5 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 13 years.
  2. Evidence of primary hyperparathyroidism.
  3. Ability to understand a written document, and the willingness to sign it.

Exclusion criteria

Exclusion Criteria:

1. Unlikely to comply with protocol procedures, restrictions and requirements and judged by the Investigator to be unsuitable for participation.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Access details

Study type
Expanded access
Access type
Individual patients · Treatment IND/protocol

Available treatment

  • DrugFluorocholineStudies of FluorocholineFluorocholine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A dose of 4-7 millicurie (mCi) +/- 10% of radiotracer 18F-Fluorocholine (FCH) manufactured at UCSF will be given intravenously.

    Also known as: FCH, 18F-fluorocholine (fluoromethyl-(2-hydroxyethyl)-dimethylazanium)

  • ProcedurePositron emission tomography (PET)

    A scan is a procedure that produces images of organs and tissues used in conjunction with a radiotracer.

    Also known as: PET Scan

06

Where to request access

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT07218224
Lead sponsor
Thomas Hope
Responsible party
Thomas Hope (Principal Investigator, University of California, San Francisco) — Sponsor-investigator
First posted
Oct 20, 2025
Last update
Oct 20, 2025

Study contacts

Maya Aslam
Contact
maya.aslam@ucsf.edu
(415)514-8987
Thomas Hope, MD
principal investigator · University of California, San Francisco
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion